Search hospitals > California > Palo Alto
Stanford Cancer Institute Palo Alto
Claim this profilePalo Alto, California 94304
Global Leader in Cancer
Global Leader in Lymphoma
Conducts research for Leukemia
Conducts research for Breast Cancer
Conducts research for Tumors
556 reported clinical trials
66 medical researchers
Summary
Stanford Cancer Institute Palo Alto is a medical facility located in Palo Alto, California. This center is recognized for care of Cancer, Lymphoma, Leukemia, Breast Cancer, Tumors and other specialties. Stanford Cancer Institute Palo Alto is involved with conducting 556 clinical trials across 534 conditions. There are 66 research doctors associated with this hospital, such as Robert Lowsky, MD, Andrei Iagaru, MD, Christopher Chen, and Sunil A. Reddy.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lymphoma
Global LeaderStage IV
Stage III
Stage II
Top PIs
Robert Lowsky, MDStanford University1 year of reported clinical research
Studies Acute Lymphoblastic Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
12 reported clinical trials
20 drugs studied
Andrei Iagaru, MDStanford University, School of Medicine7 years of reported clinical research
Studies Adenocarcinoma
Studies Prostate Cancer
14 reported clinical trials
20 drugs studied
Christopher ChenStanford Cancer Institute1 year of reported clinical research
Studies Colorectal Cancer
Studies Cancer
12 reported clinical trials
18 drugs studied
Sunil A. ReddyStanford Cancer Institute Palo Alto8 years of reported clinical research
Studies Melanoma
Studies Skin Cancer
10 reported clinical trials
14 drugs studied
Clinical Trials running at Stanford Cancer Institute Palo Alto
Breast Cancer
Squamous Cell Carcinoma
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Diffuse Large B-Cell Lymphoma
Prostate Cancer
Lymphoma
Oropharyngeal Carcinoma
Leukemia
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Stanford Cancer Institute Palo Alto?
Stanford Cancer Institute Palo Alto is a medical facility located in Palo Alto, California. This center is recognized for care of Cancer, Lymphoma, Leukemia, Breast Cancer, Tumors and other specialties. Stanford Cancer Institute Palo Alto is involved with conducting 556 clinical trials across 534 conditions. There are 66 research doctors associated with this hospital, such as Robert Lowsky, MD, Andrei Iagaru, MD, Christopher Chen, and Sunil A. Reddy.
Where is Stanford Cancer Institute Palo Alto located?
**Directions to Stanford Cancer Institute Palo Alto:**
- **By Car:** Exit at Page Mill Road and proceed east. Turn right onto Deer Creek Road, then left at Arastradero Road. The hospital is located at 1050 Arastradero Road.
- **By Shuttle:** Utilize the Marguerite Shuttle Line X and Line Y for service between the Palo Alto Transit Center and the School of Medicine.
Who should I call to ask about financial aid or insurance network?
**Stanford Cancer Institute Palo Alto - Financial and Patient Care Contacts**
- **Financial Assistance and Insurance Inquiries:** Contact the Financial Counseling department at **844-498-2900**. Available Monday-Friday, 8 a.m.-5 p.m.
- **Patient Care Contacts:** For specific patient care, reach out to the Stanford Clinical Cancer Center at **650.498.6000**.
What insurance does Stanford Cancer Institute Palo Alto accept?
The Stanford Cancer Institute Palo Alto accepts most major commercial health plans, including HMO, PPO, EPO, and POS plans, covering hospital and specialist physician services for cancer care. However, the ability to choose a Stanford Health Care physician as a primary care physician varies by plan; for example, HMO plan holders cannot select a Stanford Health Care physician as their primary care physician but can be referred for cancer care services. For the most accurate information regarding coverage, contact your employer's benefit department or your health plan, and to verify if Stanford Health Care is in-network with your specific plan, call the Anthem member services department with Stanford Health Care's Tax ID number (77-0465765).
What awards or recognition has Stanford Cancer Institute Palo Alto received?
The Stanford Cancer Institute in Palo Alto, California, is recognized as a Comprehensive Cancer Center by the National Cancer Institute. This prestigious designation highlights the institute's dedication to excellence in cancer research, encompassing basic, translational, clinical, and population-based studies. With over 450 members from diverse disciplines, the institute aims to translate research advances into improved treatments, supporting activities across Stanford University, Stanford Health Care, and Lucile Packard Children’s Hospital Stanford.